New hope for duchenne: Long-Term safety trial of WVE-N531 underway
NCT ID NCT07209332
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 30 times
Summary
This study is for people with Duchenne muscular dystrophy who have already taken the experimental drug WVE-N531 in a previous study. The goal is to check the drug's long-term safety and how well it works over time. Participants will receive the drug intravenously and undergo regular health checks, including heart and lung tests, as well as physical performance measures like walking and climbing stairs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Istiklal Hospital/ Clinical Research Unit
Amman, Jordan
-
Oxford Children's Hospital, Oxford University Hospitals NHS Foundation Trust
Headington, Oxford, OX3 9DU, United Kingdom
-
The Specialty Hospital (TSH)/ Advanced Clinical Center
Amman, Jordan
Conditions
Explore the condition pages connected to this study.